TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31805862

Group type: EXPERIMENTAL
Intervention: Single dose of Rifampicin (SDR) at double the regular dose (20 mg/kg) provided to eligible contacts aged two years and above in arms 2, 3, and 4.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No PEP provided (Arm 1 - comparator).
Number of subjects: 0
Study: 28592299

Group type: EXPERIMENTAL
Intervention: Real biofield therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 62
Study: 26466314

Group type: EXPERIMENTAL
Intervention: Dietary n-3 polyunsaturated fatty acids (PUFAs) intake, mean intake 2.0 ± 1.3 g/day
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dietary alpha-linolenic acid (ALA) intake, mean intake 1.5 ± 1.0 g/day
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ratio of n-6/n-3 PUFAs, mean ratio 9.5 ± 6.7 g/day
Number of subjects: 111
Study: 23549520

Group type: EXPERIMENTAL
Intervention: Prednisone and valacyclovir plus physical therapy (n = 39)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Pharmacological therapy only (n = 48)
Number of subjects: 87
Study: 21165628

Group type: EXPERIMENTAL
Intervention: L-arabinose (2 g) with sucrose (40 g)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sucrose (40 g) without L-arabinose
Number of subjects: 21
Study: 18836708

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17722836

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15687760

Group type: EXPERIMENTAL
Intervention: Elderly health promotion program (16 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 64
Study: 11719117

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 116
Study: 9413958

Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 20 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 40 mg every other day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Recombinant interferon alpha2a (rIFN-alpha2a) at 3 x 10(6) IU s.c. every other day
Number of subjects: 12
Study: 8386921

Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diltiazem (calcium antagonist)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Furosemide and Atenolol (loop diuretic and beta-blocker)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lisinopril and Diltiazem
Number of subjects: 30

Group type: COMPARATOR
Intervention: Furosemide and Atenolol
Number of subjects: 30
Study: 3318429

Group type: EXPERIMENTAL
Intervention: 1,000 mg nabumetone once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: 250 mg naproxen twice daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nabumetone (open-label treatment)
Number of subjects: 100
Study: 28426624

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg daily for 1 week, then up to 50 mg daily for 8 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27425658

Group type: EXPERIMENTAL
Intervention: Fixed Sequence (Random Interval 25 s schedule of reinforcement, correct feeder changed every 3 min, repeated four times)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Variable Sequence (Random Interval 25 s schedule of reinforcement, correct feeder changed in a randomized order)
Number of subjects: 6
Study: 25911587

Group type: EXPERIMENTAL
Intervention: LightCycler® SeptiFast PCR test
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard blood culture (BC) testing
Number of subjects: 78
Study: 23524365

Group type: EXPERIMENTAL
Intervention: Massage (10 minutes of massage of the trapezius muscle)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active exercise (10 minutes of shoulder shrugs with increasing elastic resistance)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive control (contralateral shoulder without treatment)
Number of subjects: 20
Study: 21383004

Group type: EXPERIMENTAL
Intervention: Night-time ingestion of antihypertensives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morning ingestion of antihypertensives
Number of subjects: 0
Study: 19109560

Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusions (150-<300 x 10(9) platelets/product)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard-dose platelet transfusions (300-600 x 10(9) platelets/product)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusions
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard-dose platelet transfusions
Number of subjects: 119
Study: 17364286

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus N‐acetyl cysteine
Number of subjects: 573

Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 573
Study: 15187171

Group type: EXPERIMENTAL
Intervention: Bayley Infant Neurodevelopmental Screener (BINS) administered at 6 and 13 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Bayley Scales of Infant Development, second edition (BSID‐II) administered at 24 months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BINS with cut score set below 90
Number of subjects: 106
Study: 11159994

Group type: EXPERIMENTAL
Intervention: Soluble toxoids (n = 5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toxoids adsorbed to alum (n = 5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Toxoids adsorbed to alum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 30
Study: 10211048

Group type: EXPERIMENTAL
Intervention: HF and red-pepper (10 g) meal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HC and red-pepper meal
Number of subjects: 13

Group type: COMPARATOR
Intervention: HF meal
Number of subjects: 13

Group type: COMPARATOR
Intervention: HC meal
Number of subjects: 13
Study: 8788579

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transaxillary first rib resection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Supraclavicular decompression (reoperation)
Number of subjects: 32
Study: 2224198

Group type: EXPERIMENTAL
Intervention: Behaviourally‐based self‐help manual
Number of subjects: 107

Group type: COMPARATOR
Intervention: General advice and information booklet (Control)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Self-help manual with opportunity to make progress reports to a telephone answering service
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Self-help manual with opportunity to make telephoned progress reports to an interviewer
Number of subjects: 107
Study: 74324

Group type: EXPERIMENTAL
Intervention: High ability to concentrate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Average ability to concentrate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low ability to concentrate
Number of subjects: 21
Study: 26808357

Group type: EXPERIMENTAL
Intervention: Ctrough model for digoxin
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Cmax model for digoxin
Number of subjects: 452
Study: 28390503

Group type: EXPERIMENTAL
Intervention: Interactive media‐based, computer‐delivered depression treatment program (imbPST)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No Treatment Control (NTC)
Number of subjects: 45
Study: 26297323

Group type: EXPERIMENTAL
Intervention: Experimental treatment (automated texting smoking intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention control (not specified in detail)
Number of subjects: 200
Study: 26678710

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1g every 4 hours for 72 hours)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline) (0.9% saline every 4 hours for 72 hours)
Number of subjects: 41
Study: 24633277

Group type: EXPERIMENTAL
Intervention: 24-hour antibiotic regimen (Ampicillin/Cloxacillin and Metronidazole)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 7-day antibiotic regimen (Ampicillin/Cloxacillin and Metronidazole)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cost of antibiotics for short term prophylaxis
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cost of antibiotics for long term prophylaxis
Number of subjects: 200
Study: 21920501

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for pathological gambling plus a standard drug therapy for schizophrenia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard drug therapy for schizophrenia
Number of subjects: 44
Study: 18333946

Group type: EXPERIMENTAL
Intervention: pH-balanced gel (pH 3.8-4.2) with regular size, non-applicator tampons
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Existing lubricating gel (pH 5.1) with regular size, non-applicator tampons
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-lubricated tampons
Number of subjects: 98
Study: 17157123

Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 14748202

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 12218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study: 10925341

Group type: EXPERIMENTAL
Intervention: Stent
Number of subjects: 400

Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 400
Study: 9528197

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg thrice daily for 14 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Amoxycillin (twice daily for 14 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 6 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Number of subjects: 123
Study: 7930131

Group type: EXPERIMENTAL
Intervention: Oral Temperature (OT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Axillary Temperature (AT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Tympanic Membrane Temperature (TMT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Rectal Temperature (RT)
Number of subjects: 65
Study: 3219156

Group type: EXPERIMENTAL
Intervention: KW-3049 (benidipine hydrochloride) 2 x 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine 2 x 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KW-3049 (benidipine hydrochloride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KW-3049 (benidipine hydrochloride) and Nifedipine
Number of subjects: 0
Study: 31959549

Group type: EXPERIMENTAL
Intervention: Transurethral resection (TUR)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Transurethral coagulation (TUC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Both TUR and TUC
Number of subjects: 126
Study: 29325517

Group type: EXPERIMENTAL
Intervention: The Daily Mile (15 minutes of running or walking integrated into the school day for 12 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: The Daily Mile
Number of subjects: 40
Study: 26879683

Group type: EXPERIMENTAL
Intervention: DHEA plus climen
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: DHEA plus climen (high-FSH subgroup)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: DHEA plus climen (low-FSH subgroup)
Number of subjects: 124

Group type: COMPARATOR
Intervention: DHEA
Number of subjects: 124
Study: 25782347

Group type: EXPERIMENTAL
Intervention: Dry Eye Disease (DED) group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 23038989

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 1061

Group type: COMPARATOR
Intervention: CE 0.45 mg/MPA 1.5 mg
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 21436597

Group type: EXPERIMENTAL
Intervention: Valsartan add-on treatment
Number of subjects: 3031

Group type: COMPARATOR
Intervention: Non-ARB treatment (Control)
Number of subjects: 3031

Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 3031
Study: 19159566

Group type: EXPERIMENTAL
Intervention: Drug-resistant regimen (3RFT AM Ofx Pto PAS-INH/5RFT Ofx Pto PAS-INH)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Retreatment regimen (3 H3R3Z3E3S3/5 H3R3E3)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: MDR-TB patients on drug-resistant regimen
Number of subjects: 154

Group type: COMPARATOR
Intervention: MDR-TB patients on retreatment regimen
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Drug-resistant regimen
Number of subjects: 154

Group type: COMPARATOR
Intervention: Retreatment regimen
Number of subjects: 154
Study: 16512974

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional palpation method (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dorsiflexion effect on artery size
Number of subjects: 30
Study: 14634601

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Midazolam/Flumazenil
Number of subjects: 32
Study: 10759030

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 8837903

Group type: EXPERIMENTAL
Intervention: Moclobemide 400 mg daily
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study: 7908356

Group type: EXPERIMENTAL
Intervention: Immediate zidovudine (250 mg four times daily)
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Deferred zidovudine (placebo)
Number of subjects: 1749
Study: 3067330

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (De‐Nol) 300 mg four times daily with ASA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin (ASA) 2.5 g plus placebo
Number of subjects: 10
Study: 29404725

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg + MTX
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + MTX
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg + MTX
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg + MTX
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg + MTX
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg + MTX
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Number of subjects: 9753

Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 9753

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg + MTX, Sirukumab 100 mg + MTX, Sarilumab 200 mg + MTX
Number of subjects: 9753
Study: 28490337

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional antidiabetic treatment
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sitagliptin and Conventional treatment
Number of subjects: 115
Study: 25642600

Group type: EXPERIMENTAL
Intervention: Cervical dilatation
Number of subjects: 199

Group type: COMPARATOR
Intervention: Non-dilated group
Number of subjects: 199
Study: 23343676

Group type: COMPARATOR
Intervention: EAA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EAA+ALA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EAA+CHO
Number of subjects: 21
Study: 20214441

Group type: EXPERIMENTAL
Intervention: Amoxicillin-metronidazole combination and scaling and root planing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 28
Study: 19016206

Group type: EXPERIMENTAL
Intervention: PASCAL pattern scanning laser (group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Single lesion technique (group 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional single spot laser coagulation (control)
Number of subjects: 33
Study: 16388496

Group type: EXPERIMENTAL
Intervention: Having an HIV-positive spouse
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Positive for herpes simplex virus type 2 (HSV-2)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: HSV-2-positive at baseline
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Living elsewhere
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Never having given birth
Number of subjects: 995

Group type: COMPARATOR
Intervention: History of injections or STIs
Number of subjects: 995
Study: 14647223

Group type: EXPERIMENTAL
Intervention: 5 g recombinant human lactoferrin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10914845

Group type: EXPERIMENTAL
Intervention: Semi-rigid orthoses worn in supportive shoes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Soft orthoses worn in supportive shoes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supportive shoes worn alone
Number of subjects: 28
Study: 9051165

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at Zusanli (St. 36), Sanyinjiao (Sp. 6), Hegu (L.I.4), and Neiguan (P.6) points
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural morphine (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone (1 microgram/1 microliter) microinjected into periaqueductal gray (PAG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at Zusanli (St. 36) after naloxone microinjection into PAG
Number of subjects: 0
Study: 1478801

Group type: EXPERIMENTAL
Intervention: Shouldice operation
Number of subjects: 142

Group type: COMPARATOR
Intervention: Bassini-Kirschner operation
Number of subjects: 142
Study: 6150365

Group type: EXPERIMENTAL
Intervention: Mefloquine plus pyrimethamine-sulfadoxine ('Fansidar')
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mefloquine plus qinghaosu
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mefloquine, fansidar, and qinghaosu
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Qinghaosu alone
Number of subjects: 80
Study: 31267698

Group type: EXPERIMENTAL
Intervention: ELISA-positive participants (GADA ≥ 5 U/mL)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ELISA-negative participants (GADA < 5 U/mL)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Participants with DRB1*09:01
Number of subjects: 95

Group type: COMPARATOR
Intervention: Acute-onset type 1 diabetes participants
Number of subjects: 95
Study: 28986245

Group type: EXPERIMENTAL
Intervention: AIM2ACT smartphone application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-guided asthma control condition
Number of subjects: 50
Study: 27326429

Group type: EXPERIMENTAL
Intervention: SPRINT patients
Number of subjects: 442

Group type: COMPARATOR
Intervention: non-SPRINT patients
Number of subjects: 442
Study: 24557989

Group type: EXPERIMENTAL
Intervention: On-line pre-dilution haemofiltration (HF), 36 patients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: On-line pre-dilution haemodiafiltration (HDF), 40 patients
Number of subjects: 146

Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD), 70 patients
Number of subjects: 146
Study: 22939457

Group type: EXPERIMENTAL
Intervention: web-based multimedia consent
Number of subjects: 35

Group type: COMPARATOR
Intervention: routine consent
Number of subjects: 35
Study: 20357008

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study: 17336171

Group type: EXPERIMENTAL
Intervention: Antenatal screening and treatment of mothers with penicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point-of-care decentralized screening and treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative approaches to controlling congenital syphilis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: International health agencies support
Number of subjects: 0
Study: 16303217

Group type: EXPERIMENTAL
Intervention: 10 microg at 0, 1 months (Group A)
Number of subjects: 990

Group type: COMPARATOR
Intervention: 10 microg at 0, 1 and 2 months (Group B - Control)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: 5 microg at 0, 1 and 2 months (Group C)
Number of subjects: 990
Study: 12215911

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg bid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid
Number of subjects: 60
Study: 10205213

Group type: EXPERIMENTAL
Intervention: 0.2% GTN three times daily
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Escalating dose GTN starting at 0.2% with weekly 0.1% increments to a maximum of 0.6%
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8555514

Group type: EXPERIMENTAL
Intervention: Patient questionnaire (mailed back)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Surgeon follow‐up card
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Patient questionnaire (telephoned by an infection control practitioner)
Number of subjects: 400
Study: 2378773

Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 29

Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 29
Study: 503379

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 75
Study: 31663855

Group type: EXPERIMENTAL
Intervention: Blended CBT (10 weekly face-to-face sessions and 9 web-based sessions)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard CBT (15 to 20 weekly face-to-face sessions)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Blended CBT
Number of subjects: 102